Mandate

Vinge advises Yubico in the merger with ACQ Bure  

ACQ Bure AB, a Swedish acquisition company (Special Purpose Acquisition Company) listed on Nasdaq Stockholm and Yubico AB have signed a merger agreement and adopted a joint merger plan to combine ACQ and Yubico.

Yubico is a leading provider of multi-factor cybersecurity solutions. Yubico’s hardware-based security key, YubiKey, is a leading solution for protection against phishing attacks, and works across hundreds of consumer and enterprise applications and services. Yubico’s technology enables secure authentication, encryption, and code signing and is used by many of the world’s largest organizations and millions of users in more than 160 countries

The transaction values Yubico’s shares at 800 MUSD and is expected to be completed during the third quarter 2023, subject to, among other things, approval by the general meeting in ACQ and Yubico, respectively.

Vinge’s team consisted of Jonas Johansson, Maria Dahlin Kolvik and Gustav Wahlberg (M&A) as well as Linnea Sellström (Public M&A).

Related

Vinge advises Right Side Group, a portfolio company of Alder, in connection with the acquisition of Brandkonsultbyrån i Sverige

Brandkonsultbyrån in Sweden is a technical consultant specialising in structural fire protection, evacuation safety and risk management. The acquisition strengthens the group’s position as a leading player in fire, risk and safety in the Nordic region.
April 17, 2026

Vinge advises Vidia Climate Fund I in connection with the acquisition and acquisition financing of ABEKA El & Kraftanläggningar AB

Vinge has acted as legal adviser to Vidia Climate Fund I in connection with the acquisition and acquisition financing of ABEKA El & Kraftanläggningar AB from Bravida and certain minority shareholders. ABEKA El & Kraftanläggningar AB is a highly specialized electrical grid services and project management provider.
April 17, 2026

Vinge adviser in the sale of SAGA Diagnostics

Vinge acted as legal adviser relating to Swedish law in connection with the sale of SAGA Diagnostics to Roche’s subsidiary Foundation Medicine.
April 16, 2026